{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:55:39Z","timestamp":1790618139188,"version":"4.1.0"},"reference-count":250,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Breast cancer is the most frequently diagnosed malignancy in women, and hormone receptor-positive disease represents its predominant subtype. Aromatase inhibitors (AIs) are a cornerstone of endocrine therapy, particularly in postmenopausal patients, but their long-term efficacy is frequently limited by intrinsic or acquired resistance. Increasing evidence indicates that epigenetic dysregulation, especially aberrant histone deacetylase (HDAC) activity, contributes to altered estrogen receptor signaling, transcriptional plasticity, activation of compensatory survival pathways, and endocrine treatment failure. This narrative review examines the biological and therapeutic interplay between aromatase and HDACs in breast cancer, integrating evidence from mechanistic studies, in vitro models, preclinical experiments, and clinical trials. HDAC inhibition may restore endocrine sensitivity by modifying chromatin accessibility, reactivating estrogen-responsive and tumor-suppressor genes, suppressing adaptive pathways such as HER2, NF-\u03baB, and PI3K\/AKT\/mTOR signaling, and promoting cell-cycle arrest and apoptosis. Preclinical studies support synergistic or sensitizing effects of combined AI\u2013HDAC inhibition, while clinical trials with entinostat, tucidinostat, panobinostat, and exemestane- or letrozole-based regimens have produced heterogeneous results. These findings suggest that endocrine\u2013epigenetic combinations may benefit selected patients rather than represent an universally effective strategy. Future clinical translation will require improved HDAC selectivity, optimized dosing, toxicity management, and validation of predictive biomarkers enabling biomarker-guided patient selection.<\/jats:p>","DOI":"10.3390\/ijms27198619","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:50:54Z","timestamp":1790614254000},"page":"8619","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting Aromatase and HDACs in Hormone Receptor-Positive Breast Cancer: Molecular Interplay, Endocrine Resistance and Therapeutic Opportunities"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4920-4760","authenticated-orcid":false,"given":"Roxana Liana","family":"Lucaciu","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Biochemistry and Clinical Laboratory, Faculty of Pharmacy, \u201cIuliu-Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0944-3161","authenticated-orcid":false,"given":"Adriana Corina","family":"Hangan","sequence":"additional","affiliation":[{"name":"Department of Inorganic Chemistry, Faculty of Pharmacy, \u201cIuliu-Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lumini\u021ba Simona","family":"Oprean","sequence":"additional","affiliation":[{"name":"Department of Inorganic Chemistry, Faculty of Pharmacy, \u201cIuliu-Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4738-5775","authenticated-orcid":false,"given":"Lucia Maria","family":"Procopciuc","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Faculty of Medicine, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Wang, R., and Yan, Z. (2025). Carcinogenesis trajectories. Front. Cell Dev. Biol., 13.","DOI":"10.3389\/fcell.2025.1671115"},{"key":"ref_2","first-page":"1617","article-title":"Hypersensitivity reactions to platinum derivatives: Findings of new predictive markers","volume":"20","author":"Cetean","year":"2015","journal-title":"J. BUON"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41576-024-00761-7","article-title":"Chromosomal instability as a driver of cancer progression","volume":"26","author":"Chen","year":"2025","journal-title":"Nat. Rev. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1007\/s12672-025-02971-9","article-title":"How chronic inflammation fuels carcinogenesis as an environmental epimutagen","volume":"16","author":"Liu","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_5","first-page":"932","article-title":"Synthesis of new N-substituted heterocyclic sulfonamides","volume":"6","author":"Hangan","year":"2012","journal-title":"Farmacia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e36905","DOI":"10.1097\/MD.0000000000036905","article-title":"Breast cancer: A review of risk factors and diagnosis","volume":"103","author":"Obeagu","year":"2024","journal-title":"Medicine"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Nardin, S., Ruffilli, B., Landolfo, T.L., Isingrini, G., Taglialatela, I., Delbarba, A., D\u2019Avanzo, F., Rossi, V., Celentano, E., and Conte, B. (2025). Aromatase inhibitors as adjuvant therapy in early breast cancer: Insights into toxicities and their management. Cancers, 17.","DOI":"10.3390\/cancers17172726"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Sancha, N., Corchado-Cobos, R., and P\u00e9rez-Losada, J. (2025). understanding susceptibility to breast cancer: From risk factors to prevention strategies. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26072993"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13058-025-02006-9","article-title":"Histone acetylation modulators in breast cancer","volume":"27","author":"Yuan","year":"2025","journal-title":"Breast Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"118372","DOI":"10.1016\/j.bmc.2025.118372","article-title":"Advances of HDAC dual inhibitors in breast cancer treatment","volume":"130","author":"Wu","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"108169","DOI":"10.1016\/j.bioorg.2025.108169","article-title":"A promising future for breast cancer therapy with hydroxamic acid-based histone deacetylase inhibitors","volume":"156","author":"Das","year":"2025","journal-title":"Bioorg. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO\/CAP Guideline Update","volume":"38","author":"Allison","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Generali, D., Berardi, R., Caruso, M., Cazzaniga, M., Garrone, O., Minchella, I., Paris, I., Pinto, C., and De Placido, S. (2023). Aromatase inhibitors: The journey from the state of the art to clinical open questions. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1249160"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Caswell-Jin, J.L., Somerfield, M.R., Khan, M.A., Kimmick, G.G., Gupta, S., Kenan, K., Peswani, N., Hershman, D.L., Ernst, B.J., and Harvey, B.E. (2026). Medical therapy for hormone receptor-positive, HER2-negative stage I-III breast cancer: ASCO Living Guideline, Version 2026.1.0. J. Clin. Oncol., 101200JCO2602034.","DOI":"10.1200\/JCO-26-02034"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"105057","DOI":"10.1016\/j.esmoop.2025.105057","article-title":"Extended adjuvant endocrine therapy in early breast cancer: Finding the individual balance","volume":"10","author":"Arecco","year":"2025","journal-title":"ESMO Open"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Khan, A., Sisodiya, S., Aftab, M., Tanwar, P., Hussain, S., and Gupta, V. (2025). Mechanisms and therapeutic strategies for endocrine resistance in breast cancer: A comprehensive review and meta-analysis. Cancers, 17.","DOI":"10.3390\/cancers17101653"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s12272-025-01583-9","article-title":"Advances and challenges of estrogen receptor-targeted agents in breast cancer","volume":"48","author":"Hu","year":"2025","journal-title":"Arch. Pharm. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"154791","DOI":"10.1016\/j.prp.2023.154791","article-title":"Hormone receptors in breast cancer: An update on the uncommon subtypes","volume":"250","author":"Wei","year":"2023","journal-title":"Pathol. Res. Pract."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Chimento, A., De Luca, A., Avena, P., De Amicis, F., Casaburi, I., Sirianni, R., and Pezzi, V. (2022). Estrogen receptors-mediated apoptosis in hormone-dependent cancers. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031242"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Clusan, L., Ferri\u00e8re, F., Flouriot, G., and Pakdel, F. (2023). A basic review on estrogen receptor signaling pathways in breast cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076834"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"188482","DOI":"10.1016\/j.bbcan.2020.188482","article-title":"Deregulated estrogen receptor signaling and DNA damage response in breast tumorigenesis","volume":"1875","author":"Rajan","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.canlet.2014.04.018","article-title":"Estrogen metabolism and breast cancer","volume":"356","author":"Samavat","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1056\/NEJMra050776","article-title":"Estrogen carcinogenesis in breast cancer","volume":"354","author":"Yager","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jsbmb.2012.12.014","article-title":"The structural biology of oestrogen metabolism","volume":"137","author":"Thomas","year":"2013","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.steroids.2016.03.017","article-title":"Recent advances in chemistry and pharmacology of 2-methoxyestradiol: An anticancer investigational drug","volume":"110","author":"Kumar","year":"2016","journal-title":"Steroids"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40169-016-0088-3","article-title":"Depurinating estrogen-DNA adducts, generators of cancer initiation: Their minimization leads to cancer prevention","volume":"5","author":"Cavalieri","year":"2016","journal-title":"Clin. Transl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e20224","DOI":"10.1016\/j.heliyon.2023.e20224","article-title":"Estrogens and the risk of breast cancer: A narrative review of literature","volume":"9","author":"Awadi","year":"2023","journal-title":"Heliyon"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e2846","DOI":"10.6061\/clinics\/2021\/e2846","article-title":"Influence of CYP19A1 gene expression levels in women with breast cancer: A systematic review of the literature","volume":"76","author":"Pereira","year":"2021","journal-title":"Clinics"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1152\/physiol.00054.2015","article-title":"Aromatase: Contributions to physiology and disease in women and men","volume":"31","author":"Blakemore","year":"2016","journal-title":"Physiology"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Ozyurt, R., and Ozpolat, B. (2022). Molecular mechanisms of anti-estrogen therapy resistance and novel targeted therapies. Cancers, 14.","DOI":"10.3390\/cancers14215206"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"311","DOI":"10.5530\/ijper.56.2.51","article-title":"Aromatase inhibitors: Development and current perspectives","volume":"56","author":"Sayyad","year":"2022","journal-title":"Indian J. Pharm. Educ. Res."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"\u0141ukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., and Stanis\u0142awek, A. (2021). breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers, 13.","DOI":"10.3390\/cancers13174287"},{"key":"ref_34","first-page":"907","article-title":"Anti-tumor effect of Euonymus Europaeus on Ehrlich tumor cells in vivo","volume":"62","author":"Sevastre","year":"2014","journal-title":"Farmacia"},{"key":"ref_35","unstructured":"Fung, T., Giovannucci, E., Anderson, C.A.M., Booth, S., Deierlein, A., Gardner, C., Hoelscher, D.M., Raynor, H., Stanford, F.C., and Talegawkar, S. (2024). Dietary Patterns and Risk of Breast Cancer: A Systematic Review."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"634","DOI":"10.31925\/farmacia.2019.4.12","article-title":"The histo-anatomical investigation and the polyphenolic profile of antioxidant complex active ingredients from three Viola species","volume":"67","author":"Jurca","year":"2019","journal-title":"Farmacia"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12968\/hmed.2021.0459","article-title":"Breast cancer: Presentation, investigation and management","volume":"83","author":"Katsura","year":"2022","journal-title":"Br. J. Hosp. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1007\/s11357-026-02257-0","article-title":"Overweight and obesity increase breast cancer risk in postmenopausal women: A meta-analysis of 38 observational studies","volume":"48","author":"Catalano","year":"2026","journal-title":"GeroScience"},{"key":"ref_39","first-page":"1604","article-title":"A comprehensive review of breast cancer: Classification, stages, risk factors, and diagnostic method","volume":"3","author":"Kumar","year":"2025","journal-title":"Int. J. Pharm. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/ijc.35427","article-title":"The estrobolome: Estrogen-metabolizing pathways of the gut microbiome and their relation to breast cancer","volume":"157","author":"Larnder","year":"2025","journal-title":"Int. J. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.steroids.2014.08.003","article-title":"Estrogen metabolites and breast cancer","volume":"99","author":"Santen","year":"2015","journal-title":"Steroids"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/phn.13504","article-title":"Modifiable risk factors for breast cancer: Insights from systematic reviews","volume":"42","author":"Li","year":"2025","journal-title":"Public Health Nurs."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/s41416-024-02833-1","article-title":"Implications of obesity and insulin resistance for the treatment of oestrogen receptor-positive breast cancer","volume":"131","author":"Javed","year":"2024","journal-title":"Br. J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41574-025-01208-7","article-title":"Oestrogen changes at menopause: Insights into obesity-associated breast risk and outcomes","volume":"22","author":"Sho","year":"2026","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Glassman, I., Le, N., Asif, A., Goulding, A., Alcantara, C.A., Vu, A., Chorbajian, A., Mirhosseini, M., Singh, M., and Venketaraman, V. (2023). The role of obesity in breast cancer pathogenesis. Cells, 12.","DOI":"10.3390\/cells12162061"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"20220822","DOI":"10.1515\/biol-2022-0822","article-title":"Low levels of sex hormone-binding globulin predict an increased breast cancer risk and its underlying molecular mechanisms","volume":"19","author":"Zhao","year":"2024","journal-title":"Open Life Sci."},{"key":"ref_47","first-page":"921","article-title":"Sex-steroid hormones and risk of postmenopausal estrogen receptor-positive breast cancer: A case-cohort analysis","volume":"35","author":"Albers","year":"2024","journal-title":"Cancer Causes Control"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/0960-0760(91)90307-Q","article-title":"Sex hormone-binding globulin: Anatomy and physiology of a new regulatory system","volume":"40","author":"Rosner","year":"1991","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s43032-022-00932-z","article-title":"Synthesis, regulatory factors, and signaling pathways of estrogen in the ovary","volume":"30","author":"Xiao","year":"2023","journal-title":"Reprod. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.hoc.2022.08.006","article-title":"Role of ovarian suppression in early premenopausal breast cancer","volume":"37","author":"Francis","year":"2023","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"102770","DOI":"10.1016\/j.ctrv.2024.102770","article-title":"Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes","volume":"129","author":"Ma","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.22.01064","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: Long-term follow-up of the combined TEXT and SOFT trials","volume":"41","author":"Pagani","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.annonc.2026.05.704","article-title":"Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer","volume":"37","author":"Francis","year":"2026","journal-title":"Ann. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.2174\/0929867329666221006110528","article-title":"Effectiveness of selective estrogen receptor modulators in breast cancer therapy: An update","volume":"30","author":"Das","year":"2023","journal-title":"Curr. Med. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Mitra, S., Lami, M.S., Ghosh, A., Das, R., Tallei, T.E., Islam, F., Dhama, K., Begum, M.Y., and Aldahish, A. (2022). Hormonal therapy for gynecological cancers: How far has science progressed toward clinical applications?. Cancers, 14.","DOI":"10.3390\/cancers14030759"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1001\/jamaoncol.2016.1897","article-title":"Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: A systematic review and meta-analysis","volume":"2","author":"Spring","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1634\/theoncologist.2017-0423","article-title":"Estrogen receptor-positive breast cancer: Exploiting signaling pathways implicated in endocrine resistance","volume":"23","author":"Brufsky","year":"2018","journal-title":"Oncologist"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.3747\/co.25.3735","article-title":"Aromatase inhibitors in premenopausal women with breast cancer: The state of the art and future prospects","volume":"25","author":"Pistelli","year":"2018","journal-title":"Curr. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrd1031","article-title":"Tamoxifen: A most unlikely pioneering medicine","volume":"2","author":"Jordan","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"103861","DOI":"10.1016\/j.critrevonc.2022.103861","article-title":"New steps on an old path: Novel estrogen receptor inhibitors in breast cancer","volume":"180","author":"Pagliuca","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Iacopetta, D., Ceramella, J., Baldino, N., Sinicropi, M.S., and Catalano, A. (2023). Targeting breast cancer: An overlook on current strategies. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043643"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.2174\/1871520620666200627204105","article-title":"Aromatase inhibitors for the treatment of breast cancer: A journey from the scratch","volume":"20","author":"Ratre","year":"2020","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Kotb, M.A., Abdelmawgood, I.A., and Ibrahim, I.M. (2024). Pharmacophore-based virtual screening, molecular docking, and molecular dynamics investigation for the identification of novel, marine aromatase inhibitors. BMC Chem., 18.","DOI":"10.1186\/s13065-024-01350-9"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"107607","DOI":"10.1016\/j.bioorg.2024.107607","article-title":"Aromatase inhibitors for the treatment of breast cancer: An overview (2019\u20132023)","volume":"151","author":"Bhatia","year":"2024","journal-title":"Bioorg. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Luo, H., Sun, Y., and Xu, T. (2025). Application status and research progress of targeted therapy drugs for hormone receptor-positive breast cancer. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1513836"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ejmech.2017.11.057","article-title":"Potent aromatase inhibitors and molecular mechanism of in hibitory action","volume":"143","author":"Kang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/bs.acr.2025.08.002","article-title":"Epigenetic mechanisms and therapeutic advances in breast cancer: From molecular insights to clinical applications","volume":"168","author":"Mir","year":"2025","journal-title":"Adv. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.2009.23.1274","article-title":"Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen","volume":"28","author":"Dowsett","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1056\/NEJMoa1811714","article-title":"Overall survival with Fulvestrant plus Anastrazole in metastatic breast cancer","volume":"380","author":"Mehta","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(10)62312-4","article-title":"Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): A randomised phase 3 trial","volume":"377","author":"Rea","year":"2011","journal-title":"Lancet"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1200\/JCO.2016.69.2871","article-title":"Comparative efficacy and safety of adjuvant Letrozole versus Anastrozole in postmenopausal patients with hormone receptor- positive, node-positive early breast cancer: Final results of the randomized phase III Femara versus Anastrozole clinical evaluation (FACE) Trial","volume":"35","author":"Smith","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: Pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"48","DOI":"10.7812\/TPP\/14-241","article-title":"Breast cancer survivorship: A comprehensive review of long-term medical issues and lifestyle recommendations","volume":"19","author":"Bodai","year":"2015","journal-title":"Perm. J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"106729","DOI":"10.1016\/j.jsbmb.2025.106729","article-title":"The current landscape of aromatase inhibitors for the treatment of estrogen receptor-positive breast carcinoma","volume":"250","author":"Bhutani","year":"2025","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.amjsurg.2018.07.052","article-title":"Optimizing adjuvant endocrine therapy for early ER+ breast cancer: An update for surgeons","volume":"217","author":"Wazir","year":"2019","journal-title":"Am. J. Surg."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"zrae100","DOI":"10.1093\/bjsopen\/zrae100","article-title":"Surgical outcomes of neoadjuvant endocrine treatment in early breast cancer: Meta-analysis","volume":"8","author":"Brett","year":"2024","journal-title":"BJS Open"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Chen, P., Li, B., and Ou-Yang, L. (2022). Role of estrogen receptors in health and disease. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.839005"},{"key":"ref_78","first-page":"e51287","article-title":"endocrine changes in postmenopausal women: A comprehensive view","volume":"15","author":"Motlani","year":"2023","journal-title":"Cureus"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1210\/clinem\/dgae458","article-title":"Adipose tissue sex steroids in postmenopausal women with and without menopausal hormone therapy","volume":"110","author":"Robciuc","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41392-024-01929-7","article-title":"Sex difference in human diseases: Mechanistic insights and clinical implications","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_81","first-page":"663","article-title":"Adjuvant endocrine therapy in premenopausal women with breast cancer","volume":"13","author":"Kadakia","year":"2015","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"113037","DOI":"10.1016\/j.ejmech.2020.113037","article-title":"Engagement of phytoestrogens in breast cancer suppression: Structural classification and mechanistic approach","volume":"213","author":"Tanwar","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/jnci\/djab022","article-title":"Patient-reported outcomes and long-term nonadherence to aromatase inhibitors","volume":"113","author":"Hershman","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1080\/14656566.2024.2425727","article-title":"Managing the neuroinflammatory pain of endometriosis in light of chronic pelvic pain","volume":"25","author":"Pergolizzi","year":"2024","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/jebm.12548","article-title":"Exploring patient medication adherence and data mining methods in clinical big data: A contemporary review","volume":"6","author":"Xu","year":"2023","journal-title":"J. Evid. Based Med."},{"key":"ref_86","first-page":"719","article-title":"The lived experience of patients with breast cancer on adjuvant endocrine therapy: Side effects and coping strategies during the first year of medication initiation","volume":"31","author":"Gomaa","year":"2023","journal-title":"Support. Care Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Zhao, L., Liu, Y., Zhang, J., Zheng, L., and Zheng, M. (2024). Adverse event profiles of the third-generation aromatase inhibitors: Analysis of spontaneous reports submitted to FAERS. Biomedicines, 12.","DOI":"10.3390\/biomedicines12081708"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"8339","DOI":"10.1021\/acs.jmedchem.3c00136","article-title":"Targeting the estrogen receptor for the treatment of breast cancer: Recent advances and challenges","volume":"66","author":"Rej","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_89","first-page":"234","article-title":"Unlocking the potential of aromatase inhibitors: Recent advances in drug design, synthesis, docking activity, and in vitro bioactivity evaluations","volume":"3","author":"Navaei","year":"2023","journal-title":"Synth. Sinter."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/978-3-031-33602-7_9","article-title":"Mechanisms of endocrine resistance in hormone receptor-positive breast cancer","volume":"188","author":"Marra","year":"2023","journal-title":"Cancer Treat. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1002\/mco2.265","article-title":"Understanding and targeting resistance mechanisms in cancer","volume":"4","author":"Lei","year":"2023","journal-title":"MedComm"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"114643","DOI":"10.1016\/j.biopha.2023.114643","article-title":"Overcoming cancer multi-drug resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges","volume":"162","author":"Duan","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41568-022-00454-5","article-title":"Therapy resistance: Opportunities created by adaptive responses to targeted therapies in cancer","volume":"22","author":"Labrie","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Dong, C., Wu, J., Chen, Y., Nie, J., and Chen, C. (2021). Activation of PI3K\/AKT\/mTOR pathway causes drug resistance in breast cancer. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.628690"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13058-021-01462-3","article-title":"ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer","volume":"23","author":"Brett","year":"2021","journal-title":"Breast Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Bou Antoun, N., and Chioni, A.M. (2023). Dysregulated signalling pathways driving anticancer drug resistance. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202307.1284.v1"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Khatpe, A.S., Adebayo, A.K., Herodotou, C.A., Kumar, B., and Nakshatri, H. (2021). Nexus between PI3K\/AKT and estrogen receptor signaling in breast cancer. Cancers, 13.","DOI":"10.3390\/cancers13030369"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Miziak, P., Baran, M., B\u0142aszczak, E., Przybyszewska-Podstawka, A., Ka\u0142afut, J., Smok-Kalwat, J., Dmoszy\u0144ska-Graniczka, M., Kie\u0142bus, M., and Stepulak, A. (2023). Estrogen receptor signaling in breast cancer. Cancers, 15.","DOI":"10.3390\/cancers15194689"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Yip, H.Y.K., and Papa, A. (2021). Signaling pathways in cancer: Therapeutic targets, combinatorial treatments, and new developments. Cells, 10.","DOI":"10.3390\/cells10030659"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Ponomarenko, I., Pasenov, K., Churnosova, M., Sorokina, I., Aristova, I., Churnosov, V., Ponomarenko, M., Reshetnikova, Y., Reshetnikov, E., and Churnosov, M. (2024). Obesity-dependent association of the rs10454142 PPP1R21 with breast cancer. Biomedicines, 12.","DOI":"10.3390\/biomedicines12040818"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Ponomarenko, I., Pasenov, K., Churnosova, M., Sorokina, I., Aristova, I., Churnosov, V., Ponomarenko, M., Reshetnikov, E., and Churnosov, M. (2024). Sex-hormone-binding globulin gene polymorphisms and breast cancer risk in caucasian women of Russia. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25042182"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Pavlova, N., Demin, S., Churnosov, M., Reshetnikov, E., Aristova, I., Churnosova, M., and Ponomarenko, I. (2022). Matrix metalloproteinase gene polymorphisms are associated with breast cancer in the caucasian women of Russia. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232012638"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Pavlova, N., Demin, S., Churnosov, M., Reshetnikov, E., Aristova, I., Churnosova, M., and Ponomarenko, I. (2022). The modifying effect of obesity on the association of matrix metalloproteinase gene polymorphisms with breast cancer risk. Biomedicines, 10.","DOI":"10.3390\/biomedicines10102617"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"266","DOI":"10.5483\/BMBRep.2020.53.5.045","article-title":"Analysis of opposing histone modifications H3K4me3 and H3K27me3 reveals candidate diagnostic biomarkers for TNBC and gene set prediction combination","volume":"53","author":"Park","year":"2020","journal-title":"BMB Rep."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"146463","DOI":"10.1016\/j.gene.2022.146463","article-title":"The key role of differential broad H3K4me3 and H3K4ac domains in breast cancer","volume":"826","author":"Barnon","year":"2022","journal-title":"Gene"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1042\/bj20021321","article-title":"Histone deacetylases (HDACs): Characterization of the classical HDAC family","volume":"370","author":"Caron","year":"2003","journal-title":"Biochem. J."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Wang, H., Zhan, Z., Gan, L., and Bai, O. (2025). Mechanisms of HDACs in cancer development. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1529239"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Tian, J., Han, M., Song, F., Liu, Y., Shen, Y., and Zhong, J. (2025). Advances of HDAC inhibitors in tumor therapy: Potential applications through immune modulation. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1576781"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/17446651.2023.2183840","article-title":"HDACs as an emerging target in endocrine tumors: A comprehensive review","volume":"18","author":"Klieser","year":"2023","journal-title":"Expert. Rev. Endocrinol. Metab."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"107883","DOI":"10.1016\/j.bioorg.2024.107883","article-title":"The pivotal role of histidine 976 in human histone deacetylase 4 for enzyme function and ligand recognition","volume":"153","author":"Schweipert","year":"2024","journal-title":"Bioorg. Chem."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Gunes, S., Hekim, N., Ergun, S., Alkan, E.N., and Can, C. (2025). Histone and Non-Histone Reversible Acetylation in Development, Aging, and Disease, Springer.","DOI":"10.1007\/978-3-031-91459-1_1"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"26694","DOI":"10.1074\/jbc.M803514200","article-title":"Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain","volume":"283","author":"Bottomley","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12094-025-03995-x","article-title":"Clinical progress and functional modalities of HDAC inhibitor-based combination therapies in cancer treatment","volume":"28","author":"Talom","year":"2026","journal-title":"Clin. Transl. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3892\/ol.2026.15497","article-title":"Histone deacetylases: Function in tumor development and therapeutic prospects (Review)","volume":"31","author":"Lin","year":"2026","journal-title":"Oncol. Lett."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.gene.2005.09.010","article-title":"Acetylation and deacetylation of non-histone proteins","volume":"363","author":"Glozak","year":"2005","journal-title":"Gene"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41419-023-06205-0","article-title":"Targeting the E2F1\/Rb\/HDAC1 axis with the small molecule HR488B effectively inhibits colorectal cancer growth","volume":"14","author":"Duan","year":"2023","journal-title":"Cell Death Dis."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1038\/s41467-024-48724-0","article-title":"HDAC activity is dispensable for repression of cell-cycle genes by DREAM and E2F:RB complexes","volume":"15","author":"Barrett","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.molonc.2007.01.001","article-title":"The role of histon deacetylases (HDACs) in human cancer","volume":"1","author":"Ropero","year":"2007","journal-title":"Mol. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"M\u00fcller, B.M., Jana, L., Kasajima, A., Lehmann, A., Prinzler, J., Budczies, J., Winzer, K.J., Dietel, M., Weichert, W., and Denkert, C. (2013). Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-215"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"E3669","DOI":"10.1073\/pnas.1504021112","article-title":"Structural insights into the assembly of hystone deacetylase with multiprotein complexes","volume":"112","author":"Clark","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/sj.onc.1209025","article-title":"E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer","volume":"25","author":"Lu","year":"2006","journal-title":"Oncogene"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ng.730","article-title":"FOXA1 is a key determinant of estrogen receptor function and endocrine response","volume":"43","author":"Hurtado","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1038\/onc.2016.32","article-title":"Targeting the RB-E2F pathway in breast cancer","volume":"35","author":"Johnson","year":"2016","journal-title":"Oncogene"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"117289","DOI":"10.1016\/j.celrep.2026.117289","article-title":"Comprehensive mass spectrometry screening-derived atlas of HDAC inhibitors reveals histone-specific acetylation changes","volume":"45","author":"Karki","year":"2026","journal-title":"Cell Rep."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/ijc.11403","article-title":"Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha","volume":"107","author":"Kawai","year":"2003","journal-title":"Int. J. Cancer"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/77124","article-title":"DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters","volume":"25","author":"Robertson","year":"2000","journal-title":"Nat. Genet."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/ng1531","article-title":"Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer","volume":"37","author":"Fraga","year":"2005","journal-title":"Nat. Genet."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1158\/0008-5472.CAN-08-3907","article-title":"Global Histone Modifications in Breast Cancer Correlate with Tumor Phenotypes, Prognostic Factors, and Patient Outcome","volume":"69","author":"Elsheikh","year":"2009","journal-title":"Cancer Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41419-025-07979-1","article-title":"Zinc finger protein 82 regulates p53 protein stability through histone deacetylase and enhances neo-adjuvant chemotherapy in esophageal cancer","volume":"16","author":"Peng","year":"2025","journal-title":"Cell Death Dis."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1053\/j.gastro.2008.07.078","article-title":"An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1","volume":"135","author":"Hanigan","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"30661","DOI":"10.18632\/oncotarget.25771","article-title":"SIRT1-dependent epigenetic regulation of H3 and H4 histone acetylation in human breast cancer","volume":"9","author":"Judes","year":"2018","journal-title":"Oncotarget"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Ding, J., Ye, M.T., and Zhang, S. (2025). The roles of Sirt1 in breast and gynecologic malignancies. Biology, 14.","DOI":"10.3390\/biology14111510"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"116743","DOI":"10.1016\/j.bcp.2025.116743","article-title":"Advancements in understanding the role and mechanism of sirtuin family (SIRT1-7) in breast cancer management","volume":"232","author":"Sharma","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"147704","DOI":"10.1016\/j.gene.2023.147704","article-title":"HDACs alters negatively to the tumor immune microenvironment in gynecologic cancers","volume":"885","author":"Yan","year":"2023","journal-title":"Gene"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1038\/sj.cdd.4401915","article-title":"Activation of NF-kappaB by HDAC inhibitor apicidin through Sp1-dependent de novo protein synthesis: Its implication for resistance to apoptosis","volume":"13","author":"Kim","year":"2006","journal-title":"Cell Death Differ."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/35042612","article-title":"Deacetylation of p53 modulates its effect on cell growth and apoptosis","volume":"408","author":"Luo","year":"2000","journal-title":"Nature"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12032-022-01770-4","article-title":"Differential molecular mechanistic behavior of HDACs in cancer progression","volume":"39","author":"Singh","year":"2022","journal-title":"Med. Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e07904","DOI":"10.1002\/advs.202507904","article-title":"Targeting HDAC and PARP enhances STING-dependent antitumor immunity in STING-deficient tumor","volume":"12","author":"Mao","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.3390\/molecules20033898","article-title":"Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents","volume":"20","author":"Mottamal","year":"2015","journal-title":"Molecules"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13045-024-01551-8","article-title":"Advances in targeting histone deacetylase for treatment of solid tumors","volume":"17","author":"Shi","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.7150\/jca.34091","article-title":"Histone deacetylase inhibitor MGCD0103 causes cell cycle arrest, apoptosis, and autophagy in liver cancer cells","volume":"11","author":"Liao","year":"2020","journal-title":"J. Cancer"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1515\/hsz-2017-0155","article-title":"HDAC1 triggers the proliferation and migration of breast cancer cells via upregulation of interleukin-8","volume":"398","author":"Tang","year":"2017","journal-title":"Biol. Chem."},{"key":"ref_143","first-page":"166","article-title":"Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as anti-cancer drugs","volume":"3","author":"Kim","year":"2011","journal-title":"Am. J. Transl. Res."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Bellucci, L., Dalvai, M., Kocanova, S., Moutahir, F., and Bystricky, K. (2013). Activation of p21 by HDAC inhibitors requires acetylation of H2A.Z. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0054102"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.cell.2008.03.025","article-title":"Acetylation is indispensable for p53 activation","volume":"133","author":"Tang","year":"2008","journal-title":"Cell"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/sj.onc.1205108","article-title":"Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling","volume":"21","author":"Deroanne","year":"2002","journal-title":"Oncogene"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1158\/1078-0432.CCR-06-3093","article-title":"Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: A result of hyperacetylation and inhibition of chaperone function of heat shock protein","volume":"13","author":"Fiskus","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41420-024-01895-7","article-title":"Dual inhibitors of DNMT and HDAC induce viral mimicry to induce antitumour immunity in breast cancer","volume":"10","author":"Huang","year":"2024","journal-title":"Cell Death Discov."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Yang, S., Cheng, M., Zhang, S., Wang, H., Wang, J., Zhang, X., Mi, Y., and Li, S. (2025). DNMT3A facilitates breast cancer progression via regulating ADAMTS8 mediated EGFR-MEK-ERK activation. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0321889"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.molcel.2020.08.020","article-title":"Integrating old and new paradigms of G1\/S control","volume":"80","author":"Rubin","year":"2020","journal-title":"Mol. Cell"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"113198","DOI":"10.1016\/j.celrep.2023.113198","article-title":"Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4\/6 inhibitors in breast cancer","volume":"42","author":"Kim","year":"2023","journal-title":"Cell Rep."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"RP104545","DOI":"10.7554\/eLife.104545.3","article-title":"Therapeutic benefits of maintaining CDK4\/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer","volume":"14","author":"Armand","year":"2025","journal-title":"eLife"},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Kindt, C.K., Ehmsen, S., Traynor, S., Policastro, B., Nissen, N., Jakobsen, M.K., Hundeb\u00f8l, M.F., Johansen, L.E., Bak, M., and Arbajian, E. (2025). RET inhibition overcomes resistance to combined CDK4\/6 inhibitor and endocrine therapy in ER+ breast cancer. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1497093"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Damaskos, C., Psilopatis, I., Garmpi, A., Dimitroulis, D., Nikolettos, K., Vrettou, K., Sarantis, P., Koustas, E., Kouraklis, G., and Antoniou, E.A. (2024). Evaluation of the histone deacetylase 2 (HDAC-2) expression in human breast cancer. Cancers, 16.","DOI":"10.3390\/cancers16010209"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1016\/j.apsb.2023.02.001","article-title":"Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Xu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"16045","DOI":"10.1007\/s00210-025-04251-3","article-title":"The E2F1\/SBK1 axis activates the Notch signaling pathway to accelerate the malignant progression of breast cancer","volume":"398","author":"Wang","year":"2025","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/sj.cdd.4401686","article-title":"Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis","volume":"13","author":"Zhang","year":"2006","journal-title":"Cell Death Differ."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.drudis.2019.02.003","article-title":"Emerging role of histone deacetylase inhibitors as anti-breast-cancer agents","volume":"24","author":"Ediriweera","year":"2019","journal-title":"Drug Discov. Today"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1158\/1541-7786.MCR-07-0330","article-title":"Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells","volume":"6","author":"Zhou","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s11033-024-10084-9","article-title":"Effects of a novel HDAC6-selective inhibitor\u2019s radiosensitization on cancer cells","volume":"51","author":"Hu","year":"2024","journal-title":"Mol. Biol. Rep."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-024-02553-9","article-title":"Dissecting the epigenetic orchestra of HDAC isoforms in breast cancer development: A review","volume":"42","author":"Debbarma","year":"2024","journal-title":"Med. Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"116559","DOI":"10.1016\/j.biopha.2024.116559","article-title":"Epigenetic deregulation in breast cancer microenvironment: Implications for tumor progression and therapeutic strategies","volume":"174","author":"Trnkova","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Wawruszak, A., Borkiewicz, L., Okon, E., Kukula-Koch, W., Afshan, S., and Halasa, M. (2021). Vorinostat (SAHA) and breast cancer: An overview. Cancers, 13.","DOI":"10.3390\/cancers13184700"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1039\/D5RA09034B","article-title":"HDAC inhibitors as anticancer drugs: Chemical diversity, clinical trials, challenges and perspectives","volume":"16","author":"Abdallah","year":"2026","journal-title":"RSC Adv."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nbt1272","article-title":"Dimethyl sulfoxide to vorinostat: Development of histone deacetylase inhibitors as anticancer drugs","volume":"25","author":"Marks","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1158\/1078-0432.CCR-08-2785","article-title":"Clinical studies of histone deacetylase inhibitors","volume":"15","author":"Prince","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1158\/1541-7786.MCR-07-0324","article-title":"Histone deacetylase inhibitors: Overview and perspectives","volume":"5","author":"Dokmanovic","year":"2007","journal-title":"Mol. Cancer Res."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Sun, Y., Hong, J.H., Ning, Z., Pan, D., Fu, X., Lu, X., and Tan, J. (2022). Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.932914"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2217\/fon-2016-0526","article-title":"Entinostat: A promising treatment option for patients with advanced breast cancer","volume":"13","author":"Connolly","year":"2017","journal-title":"Future Oncol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"a018713","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of histone acetylation: The histone deacetylase enzymes","volume":"6","author":"Seto","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1146\/annurev.pathol.4.110807.092250","article-title":"Mammalian sirtuins: Biological insights and disease relevance","volume":"5","author":"Haigis","year":"2010","journal-title":"Annu. Rev. Pathol."},{"key":"ref_173","unstructured":"U.S. Food and Drug Administration (2009). FDA Approves Istodax (Romidepsin) for Treatment of Cutaneous T-Cell Lymphoma."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/s00044-024-03210-6","article-title":"Design, synthesis and antitumor activity evaluation of novel benzamide HDAC inhibitors","volume":"33","author":"Cai","year":"2024","journal-title":"Med. Chem. Res."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1002\/cncr.34974","article-title":"Recent histone deacetylase inhibitors in cancer therapy","volume":"129","author":"Parveen","year":"2023","journal-title":"Cancer"},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Luo, Q., Gu, L., Tian, X., Zhao, Y., Zhang, Y., and Wang, F. (2025). histone deacetylase inhibitors promote the anticancer activity of cisplatin: Mechanisms and potential. Pharmaceuticals, 18.","DOI":"10.3390\/ph18040563"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"116129","DOI":"10.1016\/j.ejmech.2024.116129","article-title":"HDAC-targeting epigenetic modulators for cancer immunotherapy","volume":"265","author":"Cheng","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Seane, E.N., Nair, S., Vandevoorde, C., and Joubert, A. (2024). Mechanistic sequence of histone deacetylase inhibitors and radiation treatment: An overview. Pharmaceuticals, 17.","DOI":"10.20944\/preprints202404.0176.v1"},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Suraweera, A., O\u2019Byrne, K.J., and Richard, D.J. (2018). Combination therapy with histone deacetylase inhibitors (HDACi) for the treatmentof cancer: Achieving the full therapeutic potential of HDACi. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00092"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"8467","DOI":"10.1158\/1078-0432.CCR-05-1073","article-title":"Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta","volume":"11","author":"Marchion","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.7150\/ijbs.122366","article-title":"Remodeling the tumor immune environment in breast cancer via bortezomib-based combination therapy","volume":"21","author":"Huang","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1021\/acsmedchemlett.5c00500","article-title":"First-in-class potent, dual HDAC6\/proteasome inhibitors lacking a hydroxamic acid motif: Discovery of novel anti-multiple myeloma agents","volume":"17","author":"Chan","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"102211","DOI":"10.1016\/j.xcrm.2025.102211","article-title":"Augment proteasome inhibitor efficacy activates CD8+ T cell-mediated antitumor immunity in breast cancer","volume":"6","author":"Tang","year":"2025","journal-title":"Cell Rep. Med."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"7138","DOI":"10.1158\/1078-0432.CCR-08-0122","article-title":"A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: A California cancer consortium study","volume":"14","author":"Luu","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"35880","DOI":"10.1038\/s41598-025-19717-w","article-title":"Adverse drug reaction profiles of histone deacetylase inhibitors","volume":"15","author":"Begum","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"108768","DOI":"10.5306\/wjco.v16.i8.108768","article-title":"Potential risks of histone deacetylase inhibitors in cancer therapeutics and feasible combination therapeutic strategies","volume":"16","author":"Xiao","year":"2025","journal-title":"World J. Clin. Oncol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1007\/s00277-024-05691-2","article-title":"A real-world pharmacovigilance study investigating the toxicities of histone deacetylase inhibitors","volume":"103","author":"Li","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4155\/fmc.12.3","article-title":"Targeted cancer therapy: Giving histone deacetylase inhibitors all they need to succeed","volume":"4","author":"Gryder","year":"2012","journal-title":"Future Med. Chem."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: New dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"a026831","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC inhibitors in cancer development and therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40001-025-02326-8","article-title":"Targeted intervention of tumor microenvironment with HDAC inhibitors and their combination therapy strategies","volume":"30","author":"Zhang","year":"2025","journal-title":"Eur. J. Med. Res."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Manna, P.R., Ahmed, A.U., Molehin, D., Narasimhan, M., Pruitt, K., and Reddy, P.H. (2022). Hormonal and genetic regulatory events in breast cancer and its therapeutics: Importance of the steroidogenic acute regulatory protein. Biomedicines, 10.","DOI":"10.3390\/biomedicines10061313"},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Ferrari, P., Schiavone, M.L., Scatena, C., and Nicolini, A. (2025). Molecular mechanisms and therapeutic strategies to overcome resistance to endocrine therapy and CDK4\/6 Inhibitors in Advanced ER+\/HER2- breast cancer. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202503.1305.v1"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"757","DOI":"10.7150\/ijbs.9067","article-title":"Targeting histone deacetylases for cancer therapy: From molecular mechanisms to clinical implications","volume":"10","author":"Li","year":"2014","journal-title":"Int. J. Biol. Sci."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s11658-022-00344-6","article-title":"The role of epigenetic modifications in drug resistance and treatment of breast cancer","volume":"27","author":"Azargoonjahromi","year":"2022","journal-title":"Cell Mol. Biol. Lett."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41571-024-00935-6","article-title":"Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer","volume":"21","author":"Lloyd","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.celrep.2013.03.019","article-title":"SIRT1 suppresses the epithelial-to-mesenchymal transition in cancer metastasis and organ fibrosis","volume":"3","author":"Simic","year":"2013","journal-title":"Cell Rep."},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Kannan, K., Srinivasan, A., Kannan, A., and Ali, N. (2025). The underlying mechanisms and emerging strategies to overcome resistance in breast cancer. Cancers, 17.","DOI":"10.20944\/preprints202507.2452.v1"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"189097","DOI":"10.1016\/j.bbcan.2024.189097","article-title":"Epigenetic mechanisms of cancer progression and therapy resistance in estrogen-receptor (ER+) breast cancer","volume":"1879","author":"Toska","year":"2024","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Varun, D., Haque, M., Jackson-Oxley, J., Thompson, R., Kumari, A.A., Woodcock, C.L., Harris, A.E., Madhusudan, S., Rakha, E., and Rutland, C.S. (2025). epigenetic therapies in endocrine-related cancers: Past insights and clinical progress. Cancers, 17.","DOI":"10.3390\/cancers17152418"},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Marick, A., Manna, B., Khan, H., and Manna, P.R. (2026). steroidogenic acute regulatory protein in breast cancer: Mechanistic insights into pathogenesis and therapeutics. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27073117"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/s41388-026-03813-w","article-title":"ESR1 fusion proteins in breast cancer: Distinguishing oncogenic drivers from passenger events","volume":"45","author":"Gherghelas","year":"2026","journal-title":"Oncogene"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"141083","DOI":"10.1016\/j.bbapap.2025.141083","article-title":"HDAC7 influences ER-\u03b1 transcription via NCoR-HDAC3 dissociation","volume":"1873","author":"Kodikara","year":"2025","journal-title":"Biochim. Biophys. Acta Proteins Proteom."},{"key":"ref_204","unstructured":"Johnson Thomas, A.L., Karakyriakou, B., Muskus, P.C., Roberts, A.M., Rendleman, J., Warren, A., Lu, H., Birmingham, K.A., Friedman, M.K., and Goen, A.E. (2026). Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer. Mol. Oncol., early view."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13072-026-00667-0","article-title":"The impact of fulvestrant on estrogen receptor-driven chromatin dynamics in breast cancer cells","volume":"19","author":"Barlier","year":"2026","journal-title":"Epigenet. Chromatin"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s13402-024-01011-y","article-title":"Regulatory mechanisms of steroid hormone receptors on gene transcription through chromatin interaction and enhancer reprogramming","volume":"47","author":"Sun","year":"2024","journal-title":"Cell. Oncol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.ctrv.2013.03.009","article-title":"Targeting the PI3K\/AKT\/mTOR and Raf\/MEK\/ERK pathways in the treatment of breast cancer","volume":"39","author":"Saini","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1139\/bcb-2025-0158","article-title":"Divergent ER\u03b1 co-factor landscapes in gynecological cancers: Implications for disease progression and therapy","volume":"103","author":"Grindeland","year":"2025","journal-title":"Biochem. Cell Biol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1158\/1538-7445.AM2026-3226","article-title":"FOXA1 alterations drive endocrine therapy resistance through unique transcriptional and epigenomic programs in breast cancer","volume":"86","author":"Kittane","year":"2026","journal-title":"Cancer Res."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"e70404","DOI":"10.1002\/mco2.70404","article-title":"Breast cancer: Molecular pathogenesis and targeted therapy","volume":"6","author":"Samad","year":"2025","journal-title":"MedComm"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s42003-025-07606-x","article-title":"Genomic hallmarks of endocrine therapy resistance in ER\/PR+HER2- breast tumours","volume":"8","author":"Ghosh","year":"2025","journal-title":"Commun. Biol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1158\/2159-8290.CD-21-0212","article-title":"Independent drug action in combination therapy: Implications for precision oncology","volume":"12","author":"Plana","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Karagiannakos, A., Adamaki, M., Tsintarakis, A., Vojtesek, B., F\u00e5hraeus, R., Zoumpourlis, V., and Karakostis, K. (2022). Targeting oncogenic pathways in the era of personalized oncology: A systemic analysis reveals highly mutated signaling pathways in cancer patients and potential therapeutic targets. Cancers, 14.","DOI":"10.3390\/cancers14030664"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"152450","DOI":"10.1016\/j.bbrc.2025.152450","article-title":"Genomic characterization of AI resistance in hormone receptor-positive breast cancer using LTED cell line models","volume":"780","author":"Ahmad","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"bqaf127","DOI":"10.1210\/endocr\/bqaf127","article-title":"Emerging mechanisms of therapy resistance in metastatic ER+ breast cancer","volume":"166","author":"Truong","year":"2025","journal-title":"Endocrinology"},{"key":"ref_216","first-page":"36","article-title":"Decoding breast cancer treatment resistance through genetic, epigenetic, and immune-regulatory mechanisms: From molecular insights to translational perspectives","volume":"8","author":"Saha","year":"2025","journal-title":"Cancer Drug Resist."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13062-025-00653-8","article-title":"Estrogen receptor alpha dynamics and plasticity during endocrine resistance","volume":"20","author":"Sivasailam","year":"2025","journal-title":"Biol. Direct"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1158\/1538-7445.AM2025-4049","article-title":"Transcriptional regulation of FOXA1 by GATA2\/3 attenuates the antitumor effects of histone deacetylase (HDAC) inhibitors in basal-like breast cancer","volume":"85","author":"Tan","year":"2025","journal-title":"Cancer Res."},{"key":"ref_219","doi-asserted-by":"crossref","unstructured":"Alves, C.L., and Ditzel, H.J. (2023). Drugging the PI3K\/AKT\/mTOR pathway in ER+ breast cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054522"},{"key":"ref_220","doi-asserted-by":"crossref","unstructured":"Luo, Y., Sheng, R., Tan, X., and Gu, J. (2025). Role of EMT in drug resistance of breast cancer: Molecular mechanisms and therapeutic strategies. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1680751"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1074\/mcp.M115.052910","article-title":"proteomic analysis of epithelial to mesenchymal transition (EMT) reveals cross-talk between SNAIL and HDAC1 proteins in breast cancer cells","volume":"15","author":"Grassi","year":"2016","journal-title":"Mol. Cell Proteom."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"152079","DOI":"10.1016\/j.bbrc.2025.152079","article-title":"Metabolic reprogramming on breast cancer stem cells: Proliferation and self-renewal, epithelial-mesenchymal transition (EMT), and drug resistance","volume":"8","author":"Chen","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10549-025-07737-z","article-title":"Efficacy and safety of entinostat plus exemestane in hormone receptor-positive breast cancer: A systematic review meta-analysis of randomized controlled trials","volume":"212","author":"Mustafa","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s42003-023-05065-w","article-title":"SERPINA3-ANKRD11-HDAC3 pathway induced aromatase inhibitor resistance in breast cancer can be reversed by HDAC3 inhibition","volume":"6","author":"Zhou","year":"2023","journal-title":"Commun. Biol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"100110","DOI":"10.1016\/j.crphar.2022.100110","article-title":"Evaluation of synergism in drug combinations and reference models for future orientations in oncology","volume":"3","author":"Duarte","year":"2022","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1158\/2159-8290.CD-20-1638","article-title":"Overcoming resistance to tumor-targeted and immune-targeted therapies","volume":"11","author":"Aldea","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1158\/1535-7163.MCT-13-0345","article-title":"HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2","volume":"12","author":"Sabnis","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10549-012-2332-x","article-title":"Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat)","volume":"137","author":"Kubo","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1200\/JCO.2012.43.7251","article-title":"Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in post-menopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor","volume":"31","author":"Yardley","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.clbc.2015.11.003","article-title":"Phase I study of Panobinostat (LBH589) and Letrozole in postmenopausal metastatic breast cancer patients","volume":"16","author":"Tan","year":"2016","journal-title":"Clin. Breast Cancer"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S1470-2045(19)30164-0","article-title":"Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Jiang","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10549-015-3442-z","article-title":"Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer","volume":"152","author":"Schech","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1158\/0008-5472.CAN-10-2458","article-title":"Functional activation of the estrogen receptor-\u03b1 and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole","volume":"71","author":"Sabnis","year":"2011","journal-title":"Cancer Res."},{"key":"ref_234","doi-asserted-by":"crossref","unstructured":"Natarajan, U., Venkatesan, T., Radhakrishnan, V., Samuel, S., and Rathinavelu, A. (2018). Differential mechanisms of cell death induced by HDAC inhibitor SAHA and MDM2 inhibitor RG7388 in MCF-7 cells. Cells, 8.","DOI":"10.3390\/cells8010008"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1200\/JCO.21.00944","article-title":"E2112: Randomized phase III trial of endocrine therapy plus entinostat or placebo in hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN cancer research group","volume":"39","author":"Connolly","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jjco\/hyac166","article-title":"Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: Phase II randomized controlled trial","volume":"53","author":"Iwata","year":"2023","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.cell.2024.02.041","article-title":"Cancer biomarkers: Emerging trends and clinical implications for personalized treatment","volume":"187","author":"Passaro","year":"2024","journal-title":"Cell"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3892\/ol.2026.15569","article-title":"Cutting-edge advances in endocrine therapy for breast cancer (Review)","volume":"31","author":"Dong","year":"2026","journal-title":"Oncol. Lett."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11864-026-01391-3","article-title":"Beyond CDK4\/6 inhibition: Current strategies in hormone receptor-positive metastatic breast cancer","volume":"27","author":"Cetin","year":"2026","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_240","first-page":"e46860","article-title":"The impact of artificial intelligence on optimizing diagnosis and treatment plans for rare genetic disorders","volume":"15","author":"Abdallah","year":"2023","journal-title":"Cureus"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"104873","DOI":"10.1016\/j.breast.2026.104873","article-title":"AGO Breast Panel Recommendations for the use of treatment-relevant biomarkers in early and advanced breast cancer-2026 Update","volume":"89","author":"Hartkopf","year":"2026","journal-title":"Breast"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13058-026-02254-3","article-title":"Chidamide combined with fulvestrant in the treatment of HR-positive, HER2-negative advanced breast cancer after failure of previous endocrine therapy: A single-arm, single-center, phase 2 study","volume":"28","author":"Zou","year":"2026","journal-title":"Breast Cancer Res."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s12672-025-04302-4","article-title":"targeting estrogen receptor alpha in breast cancer for novel therapies resistance mechanisms and future directions","volume":"17","author":"Wu","year":"2026","journal-title":"Discov. Oncol."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41586-021-04278-5","article-title":"Multi-omic machine learning predictor of breast cancer therapy response","volume":"601","author":"Sammut","year":"2022","journal-title":"Nature"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1007\/s12672-026-05550-8","article-title":"The role of artificial intelligence in precision medicine for breast cancer","volume":"17","author":"Hu","year":"2026","journal-title":"Discov. Oncol."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"151487","DOI":"10.1016\/j.soncn.2023.151487","article-title":"Aromatase inhibitor-related symptoms reported by postmenopausal women with nonmetastatic, estrogen receptor-positive breast cancer: A systematic review","volume":"39","author":"Bentsen","year":"2023","journal-title":"Semin. Oncol. Nurs."},{"key":"ref_247","doi-asserted-by":"crossref","unstructured":"Lippi, L., de Sire, A., Folli, A., Turco, A., Moalli, S., Marcasciano, M., Ammendolia, A., and Invernizzi, M. (2024). Obesity and cancer rehabilitation for functional recovery and quality of life in breast cancer survivors: A comprehensive review. Cancers, 16.","DOI":"10.3390\/cancers16030521"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"218468","DOI":"10.1016\/j.canlet.2026.218468","article-title":"Integrating multi-omics and artificial intelligence for personalized breast cancer management: A guide to clinicians","volume":"649","author":"Sabit","year":"2026","journal-title":"Cancer Lett."},{"key":"ref_249","doi-asserted-by":"crossref","unstructured":"Liu, Y., Wang, M., Chen, D., Tan, Y., Zhang, X., and Wang, X. (2026). optimizing extended adjuvant endocrine therapy in early HR+\/HER2-\u2009breast cancer: The emerging role of genomic assays and ctDNA MRD. Adv. Ther.","DOI":"10.1007\/s12325-026-03616-1"},{"key":"ref_250","first-page":"101242","article-title":"Precision breast oncology: Molecular insights and transformative clinical strategies","volume":"47","author":"Chauhan","year":"2026","journal-title":"Cancer Treat. Res. Commun."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/19\/8619\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:57:39Z","timestamp":1790614659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/19\/8619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,26]]},"references-count":250,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["ijms27198619"],"URL":"https:\/\/doi.org\/10.3390\/ijms27198619","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,26]]}}}